Pasechnik V A, Shone C C, Hambleton P
PHLS Centre for Applied Microbiology & Research, Porton Down, Salisbury, UK.
Bioseparation. 1992;3(5):267-83.
Bacterial protein toxins and their fragments have been isolated and purified for various reasons, including the development of efficient vaccines and for methods of identification of bacterial agents causing disease. This activity continues today but a new area of bacterial protein toxin research has recently emerged. Since it was shown that toxin molecules comprise several types of biological activity within their structural domains, it was suggested to use these domains (and their combinations) as biochemical tools for developing novel agents for disease imaging and and/or relieving. In this way eukaryotic cell-receptor specific fusion toxins have been developed to prevent malignancy in human. While human clinical trials of these preparations have only recently begun, the preliminary clinical findings are promising. Also fusion proteins which combine independent immunodominant epitopes from different antigens have also been developed thus opening a way for the generation of new vaccines for both human and veterinary use. Receptor binding fragments of microbial toxins when combined with other molecules may be useful in delivering these molecules into the cell. In this way novel agents may be developed with a potential for inducing specific changes at the molecular level for the correction of metabolic disorders causing human and animal diseases. Bacterial protein toxins such as anthrax, botulinum, cholera, pertussis and tetanus for which considerable progress has been achieved in structure-function analysis are promising candidates for such research. Particularly exciting appears the idea of extending this research to the cells of the nervous system, exploiting the unique specificity of the botulinum or tetanus toxin fragments which may bring long desired methods for treatment of various disorders of the nervous system. Data on functional domains of these toxins as well as methods of purification of the whole toxins and their fragments are considered in this review as they form a base for their further structure-function analysis and engineering applications.
出于各种原因,包括开发高效疫苗以及用于鉴定引起疾病的细菌病原体的方法,人们已经分离和纯化了细菌蛋白毒素及其片段。如今这项工作仍在继续,但细菌蛋白毒素研究的一个新领域最近出现了。由于已表明毒素分子在其结构域内包含几种类型的生物活性,因此有人建议将这些结构域(及其组合)用作生化工具,以开发用于疾病成像和/或缓解的新型药物。通过这种方式,已经开发出真核细胞受体特异性融合毒素来预防人类恶性肿瘤。虽然这些制剂的人体临床试验直到最近才开始,但初步临床结果很有前景。此外,还开发了结合来自不同抗原的独立免疫显性表位的融合蛋白,从而为开发用于人类和兽医的新型疫苗开辟了道路。微生物毒素的受体结合片段与其他分子结合时,可能有助于将这些分子递送到细胞中。通过这种方式,可以开发出具有在分子水平上诱导特定变化以纠正导致人类和动物疾病的代谢紊乱的潜力的新型药物。炭疽、肉毒杆菌、霍乱、百日咳和破伤风等细菌蛋白毒素在结构-功能分析方面已取得了相当大的进展,是此类研究的有前途的候选对象。将这项研究扩展到神经系统细胞的想法尤其令人兴奋,利用肉毒杆菌或破伤风毒素片段的独特特异性,这可能带来长期以来人们所期望的治疗各种神经系统疾病的方法。本文综述了这些毒素的功能结构域数据以及全毒素及其片段的纯化方法,因为它们构成了进一步进行结构-功能分析和工程应用的基础。